publication date: Oct. 17, 2014
At its opening a decade ago, the Indiana University Health Proton Therapy Center was one of four such facilities in the U.S.
Alas, money woes struck immediately. The center has run at a deficit for most of its existence—recently losing over $3.5 million in operating costs in fiscal 2013. And now the center is a landmark once again: On Jan. 1, 2015, it will become the first proton beam center in the U.S. to be closed.
|Conversation with The Cancer Letter|
IU’s Loehrer Discusses “Business Decision” To Close Bloomington Proton Beam Center
The Cancer Letter asked Patrick Loehrer, director of the Indiana University Melvin & Bren Simon Cancer Center, to discuss his institution’s decision to close its 10-year-old proton beam center.
No other institution in the U.S. has closed such a facility.
Genentech Reps Not Welcome
Hospitals Urge Drug Maker to Reverse Policy
On Supplying Avastin, Rituxan, & Herceptin
Cancer centers and other hospitals, reeling from the loss of discounts and rebates on three widely used cancer drugs, are seeking to persuade drug maker Genentech to reverse its decision to channel these medications through six specialty distributors.
ASCO Endorses Guideline for Molecular Testing
The American Society of Clinical Oncology endorsed a joint clinical practice guideline on molecular testing published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
IARC Publishes Fourth Edition of European Code Against Cancer
The fourth edition of the European Code Against Cancer was published by the International Agency for Research on Cancer, with the participation of the European Commission.
Stand Up To Cancer Canada to Fund Two Dream Teams
Stand Up To Cancer Canada will support two, four-year cancer research dream teams with nearly $20 million USD raised by SU2C Canada collaborators and from the charity’s September telecast. The dream teams will focus their research on translational research in breast cancer and cancer stem cells.
Francis Giles named deputy director of Lurie Cancer Center
Zhu Chen honored by American Association for Cancer Research
Lili Yang receives $2.3 million award from NIH
Indiana University Simon Cancer Center re-designated as NCI cancer center
Cancer Treatment Centers of America launch fertility preservation program
Lurie Cancer Center to collaborate with Perthera Inc.
ASCO publishes survivorship care plan template
|Drugs and Targets|
FDA approves Velcade in mantle cell lymphoma
Priority Review granted to lenvatinib in thyroid cancer
Blinatumomab granted Priority Review in acute lymphoblastic leukemia